Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic v...
Omnimmune reported revenue of $0 for fiscal year 2009, and net income of -$1.76 million. In Q3 2010 (the quarter ended September 30, 2010) revenue was $0.
Figures from company filings; latest fiscal year ended December 31, 2009.
No profile data available.